Reading the graph
Ceres Pharma NV · borrower
a detector's reading of facts over time and relationships; a reading, not a fact
Consensus lender mark moved from 102 to 96 cents on cost at 2024-12-31
Why now: State NEW at the 2024-12-31 quarter end, readable when the filing landed on 2026-02-19.
Buyer classes for this family: Private credit lenders, PE sponsors, Special situations funds, Restructuring advisers, LPs and allocators.
3 BDC lender(s) hold $10M of funded debt at cost; no sponsor bridged. Borrowers this screen flags reached non-accrual at 2.38x the population rate within a year, median warning 139.0 days (stage-6 harness, non-accrual outcome). Non-accrual is the lender's own determination, not a court's: this is a mark signal, not a default prediction.
DFX product: Credit Attention / portfolio monitor
subsequent lender marks recover materially; the borrower refinances; the flagged facility is repaid
State INTENSIFIED at the 2026-06-30 quarter end, readable when the filing landed on 2026-08-13.
Rank 56.6: consequence 5, commercial 4, timeliness 2, novelty 5, confidence 4, magnitude 2, affected 4, actionability 4, measured lift 2.38
Family credit.tranche_markdown_5pt · sellable · computed today
State INTENSIFIED at the 2026-06-30 quarter end, readable when the filing landed on 2026-08-13.
State INTENSIFIED at the 2026-06-30 quarter end, readable when the filing landed on 2026-08-12.
State INTENSIFIED at the 2026-06-30 quarter end, readable when the filing landed on 2026-08-12.
State INTENSIFIED at the 2026-06-30 quarter end, readable when the filing landed on 2026-08-12.
State INTENSIFIED at the 2026-06-30 quarter end, readable when the filing landed on 2026-08-14.